Natco Pharma

NATCOPHARM (₹807.00) is trading in a weak, bearish trend across daily, weekly, and monthly horizons, confirmed by price action below the Supertrend and key long-term moving averages (50-period SMA, 200-period SMA). The ADX readings are low (18.88 daily, 15.19 monthly), indicating a lack of strong directional conviction despite the downward bias. Price is currently positioned near the upper end of its 20-day range (+70.2%) but remains significantly depressed relative to its 252-day high (-42.2% drawdown). Immediate resistance sits at ₹807.78 (0.10% above), with further hurdles at ₹818.97 and ₹828.03. Support is closely located at ₹804.66, followed by a pivot at ₹798.72. A recent downward gap on 2026-10-28 adds overhead supply pressure. While short-term returns are slightly positive over the last month (+1.3%), the stock has declined 11.6% over three months and 29.8% over six months. An active monthly Inside Bar pattern suggests consolidation, requiring a decisive break above resistance or below support to clarify the next directional move.

NATCO Pharma has completed a significant capital raise, allotting 17,058,082 equity shares at ₹750 per share on October 23, 2026. This transaction increased the company's paid-up equity share capital from approximately ₹35.82 crore to ₹39.23 crore. The formal basis of this allotment was published in newspapers on October 29, 2026. Looking ahead, the Board is scheduled to meet on November 13, 2026, to approve quarterly financial results for the period ended September 2026 and consider dividend declarations.

Market performance reflects substantial recent volatility. As of November 6, 2026, the stock closed at ₹807.00, with a market capitalization of approximately ₹15,626.74 crore. Technical indicators show a bearish trend across daily, weekly, and monthly timeframes, with the price trading below key moving averages. Year-to-date returns are negative at -9.1%, and the stock has experienced a maximum drawdown of -46.6% since the start of the data period.

Natco Pharma Limited has completed a significant capital expansion through a rights issue, increasing its paid-up equity share capital from ₹35.82 crore to ₹39.23 crore. The Fund-Raising Committee approved the allotment of 17,058,082 equity shares at ₹750 per share on October 23, 2026, following the issue's closure on October 22, 2026. This issuance diluted existing ownership stakes, with the public holding reported at 50.61% as of September 30, 2026.

In operational developments, the company’s U.S. subsidiary launched Carboplatin Injection (a generic of Paraplatin®) in collaboration with Teyro Labs Pvt Ltd on October 19, 2026, aiming to address product shortages in the U.S. market. Investors should note that the Board will meet on November 13, 2026, to approve quarterly financial results for the period ended September 2026 and consider dividend declarations. A trading window closure was in effect until October 28, 2026, to facilitate demat credit for designated persons.

NATCO Pharma’s Q1 FY2026-27 results reveal a divergence between operational efficiency and top-line momentum. Revenue from operations remained stable at ₹735.20 crore, while Profit Before Tax (PBT) rose 29% sequentially to ₹185.60 crore, driven by a significant 26% reduction in other expenses to ₹221.90 crore. However, Net Profit declined 23% to ₹206.50 crore as finance costs increased to ₹13 crore, reflecting higher borrowings that rose to ₹714 crore by Mar 2026.

Earnings quality remains robust, with Cash Flow from Operations (CFO) converting 148% of operating profit into cash in FY2026. Yet, the balance sheet shows strain: Inventory Days surged to 480 days, and ROCE dropped sharply to 17%. The TTM sales growth is -21%, and TTM net profit has contracted to ₹1,145 crore from ₹1,883 crore in FY2025. While promoter holding remains steady at ~49%, FIIs reduced their stake to 15.99%.

The key checkpoint is whether the expense discipline can sustain profitability despite rising interest costs and inventory buildup, particularly as the company invests ₹294 crore in CWIP.

NATCO Pharma (NSE) exhibits significant technical weakness and prolonged underperformance as of November 6, 2026. The stock is trading at ₹807.0, reflecting a year-to-date decline of -9.1% and a severe six-month drawdown of -29.8%. Over the past year, returns have stagnated at +0.8%, while the maximum historical drawdown stands at -46.6%, indicating substantial downside volatility with an annualized volatility of +39.0%. Technical indicators across daily, weekly, and monthly timeframes are uniformly bearish; the Supertrend direction is negative on all three horizons, and moving averages show steep downward slopes, particularly the SMA-20 slope of -5.61 on the daily chart. Immediate resistance is tight at ₹807.78 (0.10% above), suggesting limited upside momentum, while support levels begin just below at ₹804.66. The combination of high volatility, persistent negative trend signals, and deep cumulative losses underscores a challenging market setup for shareholders.